Company news

Crinetics Pharmaceuticals, Inc. news in 2025

Crinetics Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

December 10, 2025

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 9, 2025

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

December 2, 2025

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

November 19, 2025

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 9, 2025

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 5, 2025

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

October 22, 2025

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2025

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 5, 2025

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

September 24, 2025

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2025

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

August 20, 2025

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2025

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

July 12, 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

July 10, 2025

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 9, 2025

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

June 29, 2025

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

June 15, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

May 22, 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

May 14, 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2025

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

April 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 9, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

March 26, 2025

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 9, 2025

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 26, 2025

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

February 23, 2025

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

February 19, 2025

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 9, 2025

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

February 5, 2025

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2025

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

January 9, 2025

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025